Cure8 trial brief
The study is collecting genetic and clinical data to identify genes that may contribute to IBD risk across populations — information that could inform future research, risk prediction, and understanding of disease mechanisms.
Researchers studying IBD genetics, clinicians interested in genomics and IBD etiology, patients with Crohn’s disease or ulcerative colitis considering research participation, and caregivers of affected people.
This is a recruiting, observational genetics study based at Sinai Health System (Toronto) aiming to enroll about 150 participants, including people with IBD and healthy controls. Participants provide blood or saliva samples and clinical records; planned analyses include whole-exome sequencing and other genomics studies across populations.
Participation does not test treatments or assign interventions — it collects samples and data for research. Because this is a study record (trial registry entry), it describes the planned study design and goals rather than reporting results.
This is a registered, recruiting observational study (planned enrollment ~150) describing planned genomic analyses; the registry entry reports aims and design but does not provide study results. Whole-exome sequencing is planned but analyses and findings are not yet available.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study explores whether larger spleen size might play a causal role in the risk of ulcerative colitis or Crohn’s disease, using genetic data to reduce confounding. If a causal link exists, spleen volume could be a...
The work helps explain why smoking increases Crohn’s risk but seems protective for ulcerative colitis by identifying genetic loci and smoking-dependent gene expression changes that differ between the two diseases. That...
This national pediatric IBD network aims to collect clinical data and biological samples to study causes of early-onset IBD, track outcomes including intestinal healing and growth, and improve treatment strategies — work...
